Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
08/2005
08/04/2005US20050172345 Recombinant cells comprising muscarinic acetylcholine receptor 6 for use in identifying modulators for prevention and treatment of muscle, eating and nervous system disorders
08/04/2005US20050171366 Forming a diastereoselective epoxide from a chiral alpha-amino aldehyde; efficient synthesis of intermediates which are readily amenable to the large scale preparation of hydroxyethylurea-based chiral HIV protease inhibitors
08/04/2005US20050171343 Expression of lipoproteins
08/04/2005US20050171341 Methods for stabilizing proteins
08/04/2005US20050171338 Mammalian tribbles signaling pathways and methods and reagents related thereto
08/04/2005US20050171335 Novel antimicrobial peptide and use thereof
08/04/2005US20050171286 Copolymer-1 improvements in compositions of copolymers
08/04/2005US20050171192 treating or preventing reactive oxygen species (ROS)-mediated oxidative damage to bone cells and tissues; histamine receptor agonists, histamine salts, histamine prodrugs, NADPH-oxidase inhibitors, serotonin, serotonin (5HT) receptor agonists
08/04/2005US20050171146 Non-peptidic BRS-3 agonists
08/04/2005US20050171137 derivatives of Hemiasterlin or Geodiamolide G; pyrido(3,4-B)indole amides; extraction from marine sponges; anti-mitotic and carcinogenic agent; cause mitotic arrest and produce abnormal mitotic spindles
08/04/2005US20050171112 treating nervous system diorders by administering inhibitors of glutaminyl cyclase and optionally inhibitors of propyl endopeptidases, dipeptidyl aminopeptidases, secretases, endopeptidase, angiotensin converting enzyme and neuropeptide Y receptor ligands, agonists or antagonists; enzyme inhibitors
08/04/2005US20050171060 Anticancer agents and drug delivery agents with nucleotides
08/04/2005US20050171042 Compositions and their uses directed to binding proteins
08/04/2005US20050171040 Chemically synthesized double stranded molecules; hypercholesterolemia, hyperlipidemia, cardiovascular and cerebrovascular disorders, aortic stenosis, peripheral vascular disease, atherosclerosis
08/04/2005US20050171031 Method and composition for the treatment of cancer
08/04/2005US20050171025 Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
08/04/2005US20050171024 Modulating angiogenesis
08/04/2005US20050171023 Apoptosis resistance; protecting healthy cells under environmental stress
08/04/2005US20050171022 Proteaseome inhibitors for the treatment of herpesviridae infected individuals
08/04/2005US20050171021 Buffered drug formulations for transdermal
08/04/2005US20050171020 Growth factor polypeptides and nucleic acids encoding same
08/04/2005US20050171019 Administering an exendin modified with a polymer such as polyethylene glycol, gelatin and/or albumin to increase its biological half-life; treating hyperglucagonemia and diabetes, especially type II diabetes
08/04/2005US20050171018 Novel polypeptide and gene encoding the same
08/04/2005US20050171017 As antiinflammatory agent alone or in combinaton; side effect reduction of glucocorticoid treatment; acute or chronic inflammation such as autoimmune disease, allergies, asthma, chronic obstructive pulmonary disease, psoriasis, dermatitis, Inflammatory Bowel disease
08/04/2005US20050171016 Thrombospondin-2 and uses thereof
08/04/2005US20050171015 Administering an NFAT agonist; NFAT (nuclear factor of activated T cells); drug screening; screening for target genes
08/04/2005US20050171014 ligand, a linker, and a cytotoxic agent, in which the linker is FALA; cell-targeted cancer therapy
08/04/2005US20050171012 Preventives/remedies for bone/joint diseases
08/04/2005US20050171011 Depsipeptide and congeners thereof for use as immunosuppressants
08/04/2005US20050171010 vancomycin derivative multibinding agents comprising ligands covalently connected, capable of binding to a transglycosylase enzyme substrate
08/04/2005US20050171009 by addition of surfactants such as nonionic surfactants of the (poly)ethoxylated fatty acid type; storage stability to hydrophobic aggregation nuclei for several months under temperature stress
08/04/2005US20050171007 Therapeutic method
08/04/2005US20050171006 Treatment of congestive heart failure
08/04/2005US20050171005 Inhibitors of beta-catenin Serine 45 (S45) phosphorylation e.g. Dishevelled (Dvl), a Wnt protein, phosphatase PP2A, and Casein kinase I (CKI) inhibitors; enhancers such as phosphatase inhibitor okadaic acid and protein that promotes beta-catenin acetylation, FRAT; drug screening; anticancer agents
08/04/2005US20050171004 or bioactive fragments thereof; cardiac infarct scar
08/04/2005US20050171003 Use of a growth hormone or a growth hormone secretagogue for appetite-suppression or induction of satiety
08/04/2005US20050171002 Polyoxyalkylene compound and method for making
08/04/2005US20050171001 Hemostatic compositions and devices
08/04/2005US20050171000 computer aided drug design; e.g. candidate drugs to treat obesity
08/04/2005US20050170504 Method for transfer of molecular substances with prokaryontic nucleic acid-binding proteins
08/04/2005US20050170500 Methods for identifying risk of melanoma and treatments thereof
08/04/2005US20050170489 Beta-secretase enzyme compositions and methods
08/04/2005US20050170468 Anti-IL-20 receptor antibodies and binding partners and methods of using in inflammation
08/04/2005US20050170466 Equine Fc epsilon receptor alpha protein
08/04/2005US20050170461 Identifying modulators which modify ligand protein binding for human pitutary and/or mouse pancreas-derived G protein-coupled receptorl treating nervous system and infectious disorders
08/04/2005US20050170459 Thymic stromal lymphopoietin receptor molecules and uses thereof
08/04/2005US20050170449 Soluble GlcNAc phosphotransferase
08/04/2005US20050170440 Treatment and diagnosis of insulin-resistant states
08/04/2005US20050170436 Inducing specific B cell anergy to an immunogen comprising a conjugate of a nonimmunogenic valency platform molecule and an analog of the immunogen that (a) binds specifically to B cells to which the immunogen binds and (b) lacks the T cell epitope(s) of the immunogen
08/04/2005US20050170434 Modulators of lymphocyte activation, mkk3b compositions and methods of use
08/04/2005US20050170430 Diagnosis and treatment of glaucoma and methods for discovering new glaucoma therapeutic agents based on the wnt/ca2+ signaling pathway
08/04/2005US20050170413 Transport peptide amino acid sequences for use in identifying modulators for prevention and treatment of cell proliferative disorders; tissue target therapy; drug delivery
08/04/2005US20050170410 Recombinant cytokine for diagnosis, prevention and treatment of tissue-degenerating disorders
08/04/2005US20050170404 Modified human growth hormone polypeptides and their uses
08/04/2005US20050170397 Novel receptors
08/04/2005US20050170396 Using monoclonal antibodies to determine concentration of preferential membrane bound receptor in cancer cells; immunoassay
08/04/2005US20050170389 Nucleotide sequences coding ligand polypeptides for use in identifying modulators for diagnosis, prevention and treatnment of diabetes, heart and cancer disorders
08/04/2005US20050170384 Expression vector comprising nucleotide sequences coding protein with sequence similarities to chordin proteins for use as tool in identifying modulator for treatment and prevention of infection and metabolic disorders
08/04/2005US20050170382 Immunoglobulin comprising receptor for advanced glycation endproducts for treating inflammation; antiinflammtory agents
08/04/2005US20050170381 Using lymphocytes expressing jun kinase as tools in detecting modulators for treatment of cell proliferative disorders
08/04/2005US20050170374 Expression vector comprising nucleotide sequences coding protein factor for treatment, diagnosis and prevention of proliferative and differentiative disorders
08/04/2005US20050170371 Alopecia, acne, polycystic ovary disease, prostitic hypertrophy, and prostate cancer
08/04/2005US20050170366 Novel hair keratin-associated proteins
08/04/2005US20050170365 Nucleotide sequences coding modified deoxyribonuclease for treatment of pulmonary, autoimmune and/or cystic fibrosis
08/04/2005US20050170364 Novel human kinase protein and polynucleotides encoding the same
08/04/2005US20050170359 Treatment of vascular dysfunction and alzheimer's disease
08/04/2005US20050170357 Nucleotide sequences comprising Birt-Hogg-Dubé locus (BHD) for use in identifying modulator for treatment of cell proliferative disorders of kidney; antisense agents; gene expression inhibition
08/04/2005US20050170349 A purified polypeptide comprising a splice variant of AMP-activated kinase; a nucleic acid and expression vector; bioassay for modulators; antibodies for the polypeptide; improved metabolic regulation
08/04/2005US20050170348 Nuclear-envelope and nuclear-lamina binding chimeras for modulating gene expression
08/04/2005US20050170344 Chds as modifiers of the p53 pathway and methods of use
08/04/2005US20050170023 Steam extraction of amino acids under pressure for cosmetics; treatment for hair and skin
08/04/2005US20050170010 Pharmaceutical Antidiabetic Composition
08/04/2005US20050169995 Modulation of gastrointestinal epithelium proliferation through the Wnt signaling pathway
08/04/2005US20050169976 Insulin administration apparatus
08/04/2005US20050169968 Conjugates comprising a biodegradable polymer and uses therefor
08/04/2005US20050169966 Growth promoting pharmaceutical implant
08/04/2005US20050169965 Compounds with improved cartilage-inducing and/or bone-inducing activity
08/04/2005US20050169961 Implantable sensors and implantable pumps and anti-scarring agents
08/04/2005US20050169960 Implantable sensors and implantable pumps and anti-scarring agents
08/04/2005US20050169959 Medical implants and fibrosis-inducing agents
08/04/2005US20050169958 Medical implants and fibrosis-inducing agents
08/04/2005US20050169937 Attacking immune tolerant species; having at least one consensus amino acid sequence
08/04/2005US20050169936 Epithelial cell growth inhibitors
08/04/2005US20050169935 Compositions and methods for immunotherapy of cancer and infectious diseases
08/04/2005US20050169934 Computer assisted modeling of tumor antigen bound in major histocompatibility complex I groove; substituting at least first amino acid located in cytotoxic T lymphocyte epitope; reducing interference with T cell receptor binding; HER-2 related cancer
08/04/2005US20050169931 EphA2 as a therapeutic target for cancer
08/04/2005US20050169930 PSCA: prostate stem cell antigen and uses thereof
08/04/2005US20050169924 BAFF, inhibitors thereof and their use in the modulation of B-cell response
08/04/2005US20050169923 monoclonal antibody prevents the growth or differentiation of the B cell; secreted by the hybridoma; therapy of autoimmune diseases, sytematic lupus erythematosus, primary biliary cirrhosis, and idiopathic thrombocytopenic purpura; biodrug
08/04/2005US20050169922 drug screening for compounds that enhance or suppress killer T cell activity by contacting killer T cells which express biliary glycoprotein with a compound that binds biliary glycoprotein and determining the cytotoxicity or proliferation of the killer T cells relative to a control
08/04/2005US20050169920 Pecam-1 modulation
08/04/2005US20050169919 DNA encoding the amino acid sequence fusion protein; regulate T cell interactions with B7 positive cells, immune responses; treating tissue transplant rejection, graft versus host disease with immunomodulator; antiproliferative agent of lymphocyte
08/04/2005US20050169918 selectively targeting; screening an effect of a Chemokine receptor (CCR4) modulating agent; adjusting the adhesion of T cells to endothelial cells; treating inflammatory skin disease; side effect reduction without affecting on other cells
08/04/2005US20050169915 selected from heavy chains, light chains and modified variable regions; breast cancer therapy; detecting using antigen and antibody complex; immunoassay, immunotherapy
08/04/2005US20050169913 Administering a monoclonal antibody or enzyme inhibitor of prothrombinase; therapeutic treatment of bacterial and viral infections, allograft and xenograft rejection, cancer, glomerulonephritis, gastrointestinal disorders and fetal loss; inhibiting gene expression of prothrombinase
08/04/2005US20050169910 monoclonal antibody binds to TcII for inhibiting cellular uptake of vitamin B12 resulting in apoptosis; antitumor agents
08/04/2005US20050169908 administering antithrombin protein being encoded by a transgene DNA and argatroban; acute respiratory distress syndrome; respiratory system disorders
08/04/2005US20050169907 amino acid sequence peptide is derived from the N' terminus region of the 50 Kd subunit of heparanase; used in drug screening for antibody as enzyme inhibitors; antitumor agents, anticarcinogenic agents, antiinflammatory agents; autoimmune disease and kidney urogenital disorder
08/04/2005US20050169904 biodrug fusion protein comprising active mitochondrial protein or peptide, a mitochondrial membrane-permeant peptide and linking to a mitochondrial targeting sequence; targeting sequence is cleaved within the mitochondrial matrix, and not cleaved within the cellular cytoplasm; mitochondrial disorders
08/04/2005US20050169901 controlling cytokine levels by administering extract or secreted products from microorganism; biosynthesis; atheroma, degenerative vascular disease or cardiovascular disease associated with inflammation of the coronary arteries; hypotensive agents, antilipemic agents, anticholesterol agents
1 ... 1401 1402 1403 1404 1405 1406 1407 1408 1409 1410 1411 1412 1413 1414 1415 1416 1417 1418 1419 1420 1421 ... 3163